2021 대한부정맥학회 심방세동 환자의 특수 임상 상황 환자군에서 ABC Pathway 치료 지침

키워드

참고문헌 (342)

1. Van Gelder IC, "Rate control in atrial fibrillation", Lancet, 388, pp.818~828 (2016)
2. Clemo HF, "Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias", Am J Cardiol, 81, pp.594~598 (1998)
3. Laura Bonfanti, "Effectiveness and safety of electrical cardioversion for acute-onset atrial fibrillation in the emergency department: a real-world 10-year single center experience", Clinical and Experimental Emergency Medicine, 6(1), pp.64~69 (2019), 대한응급의학회[DOI]
4. Scheuermeyer FX, "Thirty-day and 1-year outcomes of emergency department patients with atrial fibrillation and no acute underlying medical cause", Ann Emerg Med, 60, pp.755~765 (2012)
5. Tisdale JE, "A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery", Am Heart J, 135, pp.739~747 (1998)
6. Bavendiek U, "Rationale and design of the DIGIT-HF trial(DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure) : a randomized, double-blind, placebo-controlled study", Eur J Heart Fail, 21, pp.676~684 (2019)
7. Darby AE, "Management of atrial fibrillation in patients with structural heart disease", Circulation, 125, pp.945~957 (2012)
8. Boriani G, "Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation(EORP-AF)pilot general registry", Int J Cardiol, 271, pp.68~74 (2018)
9. Boriani G, "Real-world management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry", Europace, 18, pp.648~657 (2016)
10. Gulizia MM, "Management of atrial fibrillation in the emergency room and in the cardiology ward : the BLITZ AF study", Europace, 21, pp.230~238 (2019)
11. Gonzalez-Pacheco H, "Clinical features and in-hospital mortality associated with different types of atrial fibrillation in patients with acute coronary syndrome with and without ST elevation", J Cardiol, 66, pp.148~154 (2015)
12. Krijthe BP, "Unrecognized myocardial infarction and risk of atrial fibrillation : the Rotterdam Study", Int J Cardiol, 168, pp.1453~1457 (2013)
13. Chao TF, "Acute myocardial infarction in patients with atrial fibrillation with a CHA2DS2-VASc score of 0 or 1 : a nationwide cohort study", Heart Rhythm, 11, pp.1941~1947 (2014)
14. Sanclemente C, "Predictors of outcome in stable outpatients with peripheral artery disease", Intern Emerg Med, 9, pp.69~77 (2014)
15. Soliman EZ, "Atrial fibrillation and risk of ST-segment-elevation versus non-ST-segment-elevation myocardial infarction : the Atherosclerosis Risk in Communities(ARIC)Study", Circulation, 131, pp.1843~1850 (2015)
16. Fauchier L, "Should atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be anticoagulated?", Stroke, 47, pp.1831~1836 (2016)
17. Kralev S, "Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography", PLoS One, 6, pp.e24964~ (2011)
18. Guimaraes PO, "Usefulness of antithrombotic therapy in patients with atrial fibrillation and acute myocardial infarction", Am J Cardiol, 123, pp.12~18 (2019)
19. Erez A, "Temporal trends and outcomes associated with atrial fibrillation observed during acute coronary syndrome : real-world data from the Acute Coronary Syndrome Israeli Survey(ACSIS), 2000-2013", Clin Cardiol, 40, pp.275~280 (2017)
20. Neumann FJ, "2018ESC", EACTS Guidelines on myocardial revascularization, 2019, pp.40, 87~165
21. Knuuti J, "2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes", Eur Heart J, 41, pp.407~477 (2020)
22. Lip GYH, "2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and", or undergoing percutaneous cardiovascular interventions : a joint consensus document of the European Heart Rhythm Association(EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions(EAPCI), and European Association of Acute Cardiac Care(ACCA)endorsed by the Heart Rhythm Society(HRS), Asia-Pacific Heart Rhythm Society(APHRS), Latin America Heart Rhythm Society(LAHRS), and Cardiac Arrhythmia Society of Southern Africa(CASSA), 2019, pp.21, 192~193
23. Gargiulo G, "Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials", Eur Heart J, 40, pp.3757~3767 (2019)
24. Potpara TS, "Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions : meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials", Europace, 22, pp.33~46 (2020)
25. Lamberts M, "Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention", J Am Coll Cardiol, 62, pp.981~989 (2013)
26. Fiedler KA, "Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation : the ISAR-TRIPLE Trial", J Am Coll Cardiol, 65, pp.1619~1629 (2015)
27. Cannon CP, "Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation", N Engl J Med, 377, pp.1513~1524 (2017)
28. Gibson CM, "Prevention of bleeding in patients with atrial fibrillation undergoing PCI", N Engl J Med, 375, pp.2423~2434 (2016)
29. Lopes RD, "Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention : a network meta-analysis of randomized controlled trials", JAMA Cardiol, 4, pp.747~755 (2019)
30. Vranckx P, "Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation(ENTRUST-AF PCI) : a randomised, open-label, phase 3b trial", Lancet, 394, pp.1335~1343 (2019)
31. Golwala HB, "Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention:a systematic review and meta-analysis of randomized clinical trials", Eur Heart J, 39, pp.1726~1735 (2018)
32. Yasuda S, "Antithrombotic therapy for atrial fibrillation with stable coronary disease", N Engl J Med, 381, pp.1103~1113 (2019)
33. Andreou I, "Ticagrelor versus clopidogrel as part of dual or triple antithrombotic therapy : a systematic review and meta-analysis", Cardiovasc Drugs Ther, 32, pp.287~294 (2018)
34. Fu A, "Ticagrelor in triple antithrombotic therapy : predictors of ischemic and bleeding complications", Clin Cardiol, 39, pp.19~23 (2016)
35. Jackson LR, "Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy : a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS Study", JACC Cardiovasc Interv, 8, pp.1880~1889 (2015)
36. Sarafoff N, "Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation", J Am Coll Cardiol, 61, pp.2060~2066 (2013)
37. Verlinden NJ, "Triple antithrombotic therapy with aspirin, P2Y12 inhibitor, and warfarin after percutaneous coronary intervention : an evaluation of prasugrel or ticagrelor versus clopidogrel", J Cardiovasc Pharmacol Ther, 22, pp.546~551 (2017)
38. Kim D, "Ideal blood pressure in patients with atrial fibrillation", J Am Coll Cardiol, 72, pp.1233~1245 (2018)
39. Piepoli MF, "2016 European Guidelines on cardiovascular disease prevention in clinical practice : the sixth joint task force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice(constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation(EACPR)", Eur Heart J, 37, pp.2315~2381 (2016)
40. Lopes RD, "Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation", N Engl J Med, 380, pp.1509~1524 (2019)
41. Gibson CM, "Prevention of bleeding in patients with atrial fibrillation undergoing PCI", N Engl J Med, 375, pp.2423~2434 (2016)
42. Cannon CP, "Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation", N Engl J Med, 377, pp.1513~1524 (2017)
43. Berge E, "Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial", Lancet, 355, pp.1205~1210 (2000)
44. Paciaroni M, "Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke : a meta-analysis of randomized controlled trials", Stroke, 38, pp.423~430 (2007)
45. Ntaios G, "Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack : a systematic review and meta-analysis of randomized controlled trials", Stroke, 43, pp.3298~3304 (2012)
46. González Toledo ME, "Atrial fibrillation detected after acute ischemic stroke: evidence supporting the neurogenic hypothesis", J Stroke Cerebrovasc Dis., 22, pp.e486~e491 (2013)
47. Steffel J, "The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation : executive summary", Europace, 20, pp.1231~1242 (2018)
48. Saxena R, "Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial", Stroke, 32, pp.2333~2337 (2001)
49. Hart RG, "Early recurrent embolism associated with nonvalvular atrial fibrillation : a retrospective study", Stroke, 14, pp.688~693 (1983)
50. Dewilde WJ, "Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention : an open-label, randomised, controlled trial", Lancet, 381, pp.1107~1115 (2013)
51. Pikija S, "Idarucizumab in dabigatran-treated patients with acute ischemic stroke receiving alteplase : a systematic review of the available evidence", CNS Drugs, 31, pp.747~757 (2017)
52. Steinberg BA, "Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants:results from ORBIT-AF II (the outcomes registry for better informed treatment of atrial fibrillation II)", J Am Heart Assoc., 7, pp.e007633~ (2018)
53. Diener HC, "Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source", N Engl J Med, 380, pp.1906~1917 (2019)
54. Hart RG, "Rivaroxaban for stroke prevention after embolic stroke of undetermined source", N Engl J Med, 379, pp.987~ (2018)
55. Healey JS, "Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation : secondary analysis of the NAVIGATE ESUS randomized clinical trial", JAMA Neurol, 76, pp.764~773 (2019)
56. Geisler T, "Apixaban for treatment of embolic stroke of undetermined source(ATTICUS randomized trial) : Rationale and study design", Int J Stroke, 12, pp.985~990 (2017)
57. Li YG, "A simple clinical risk score(C2HEST)for predicting incident atrial fibrillation in asian subjects : derivation in 471, 446 Chinese subjects, with internal validation and external application in 451, 199Korean subjects", Chest, 155, pp.510~518 (2019)
58. Sposato LA, "Diagnosis of atrial fibrillation after stroke and transient ischaemic attack : a systematic review and meta-analysis", Lancet Neurol, 14, pp.377~387 (2015)
59. Gladstone DJ, "Atrial fibrillation in patients with cryptogenic stroke", N Engl J Med, 370, pp.2467~2477 (2014)
60. Sanna T, "Cryptogenic stroke and underlying atrial fibrillation", N Engl J Med, 370, pp.2478~2486 (2014)
61. Thijs VN, "Predictors for atrial fibrillation detection after cryptogenic stroke : results from CRYSTAL AF", Neurology, 86, pp.261~269 (2016)
62. Levin LA, "A cost-effectiveness analysis of screening for silent atrial fibrillation after ischaemic stroke", Europace, 17, pp.207~214 (2015)
63. Yong JH, "Potential cost-effectiveness of ambulatory cardiac rhythm monitoring after cryptogenic stroke", Stroke, 47, pp.2380~2385 (2016)
64. Wachter R, "Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke(Find-AFRANDOMISED) : an open-label randomised controlled trial", Lancet Neurol, 16, pp.282~290 (2017)
65. Grond M, "Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke : a prospective multicenter cohort study", Stroke, 44, pp.3357~3364 (2013)
66. Li YG, "C2 HEST score and prediction of incident atrial fibrillation in poststroke patients: a french nationwide study", J Am Heart Assoc., 8, pp.e012546~ (2019)
67. Shen AY, "Racial", ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation, 2007, pp.50, 309~315
68. Ruff CT, "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials", Lancet, 383, pp.955~962 (2014)
69. Murthy SB, "Restarting anticoagulant therapy after intracranial hemorrhage : a systematic review and meta-analysis", Stroke, 48, pp.1594~1600 (2017)
70. Cuker A, "Laboratory measurement of the non-vitamin K antagonist oral anticoagulants : selecting the optimal assay based on drug, assay availability, and clinical indication", J Thromb Thrombolysis, 41, pp.241~247 (2016)
71. Salmonson T, "Non-vitamin-K oral anticoagulants and laboratory testing : now and in the future : views from a workshop at the European Medicines Agency(EMA)", Eur Heart J Cardiovasc Pharmacother, 3, pp.42~47 (2017)
72. Chai-Adisaksopha C, "Hemodialysis for the treatment of dabigatran-associated bleeding : a case report and systematic review", J Thromb Haemost, 13, pp.1790~1798 (2015)
73. Anderson I, "Management of bleeding in patients taking oral anticoagulants", JAMA, 319, pp.2032~2033 (2018)
74. Milling TJ Jr, "Safety of a four-factor prothrombin complex concentrate versus plasma for vitamin K antagonist reversal : an integrated analysis of two phase IIIb clinical trials", Acad Emerg Med, 23, pp.466~475 (2016)
75. Pollack CV Jr, "Idarucizumab for dabigatran reversal-full cohort analysis", N Engl J Med, 377, pp.431~441 (2017)
76. Connolly SJ, "Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors", N Engl J Med, 380, pp.1326~1335 (2019)
77. Levi M, "Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers", J Thromb Haemost, 12, pp.1428~1436 (2014)
78. Zahir H, "Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate", Circulation, 131, pp.82~90 (2015)
79. Isnard R, "Non-vitamin K antagonist oral anticoagulants and heart failure", Arch Cardiovasc Dis, 109, pp.641~650 (2016)
80. Xiong Q, "Non-vitamin K antagonist oral anticoagulants(NOACs)in patients with concomitant atrial fibrillation and heart failure : a systemic review and meta-analysis of randomized trials", Eur J Heart Fail, 17, pp.1192~1200 (2015)
81. Ezekowitz JA, "2017 comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure", Can J Cardiol, 33, pp.1342~1433 (2017)
82. Group NCHFGW, "National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand : guidelines for the prevention, detection, and management of heart failure in Australia 2018", Heart Lung Circ, 27, pp.1123~1208 (2018)
83. Ponikowski P, "2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association(HFA)of the ESC", Eur Heart J, 37, pp.2129~2200 (2016)
84. Kelly JP, "Rhythm control versus rate control in patients with atrial fibrillation and heart failure with preserved ejection fraction: insights from get with the guidelines-heart failure", J Am Heart Assoc, 8, pp.e011560~ (2019)
85. Kotecha D, "Efficacy of beta blockers in patients with heart failure plus atrial fibrillation : an individual-patient data meta-analysis", Lancet, 384, pp.2235~2243 (2014)
86. Filippatos G, "How to use beta-blockers in heart failure with reduced ejection fraction and atrial fibrillation", J Am Coll Cardiol, 69, pp.2897~2900 (2017)
87. Nielsen PB, "Beta-blockers in atrial fibrillation patients with or without heart failure: association with mortality in a nationwide cohort study", Circ Heart Fail, 9, pp.e002597~ (2016)
88. Yu HT, "Outcomes of rate-control treatment in patients with atrial fibrillation and heart failurea nationwide cohort study", Circ J, 82, pp.652~658 (2018)
89. Nkomo VT, "Burden of valvular heart diseases : a population-based study", Lancet, 368, pp.1005~1011 (2006)
90. Eguchi K, "Pre-operative atrial fibrillation as the key determinant of outcome of mitral valve repair for degenerative mitral regurgitation", Eur Heart J, 26, pp.1866~1872 (2005)
91. Maan A, "Impact of atrial fibrillation on outcomes in patients who underwent transcatheter aortic valve replacement", Am J Cardiol, 115, pp.220~226 (2015)
92. Ngaage DL, "Prognostic implications of preoperative atrial fibrillation in patients undergoing aortic valve replacement: is there an argument for concomitant arrhythmia surgery?", Ann Thorac Surg., 82, pp.1392~1399 (2006)
93. Lim E, "Influence of atrial fibrillation on outcome following mitral valve repair", Circulation, 104(12 Suppl 1), pp.l59~l63 (2001)
94. Philippart R, "Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease : the Loire Valley Atrial Fibrillation Project", Eur Heart J, 36, pp.1822~1830 (2015)
95. Lip GYH, "Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease : evaluating 'valvular heart disease' in a nationwide cohort study", Europace, 21, pp.33~40 (2019)
96. Philippart R, "Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project", Thromb Haemost, 115, pp.1056~1063 (2016)
97. Siontis KC, "Direct oral anticoagulants in patients with atrial fibrillation and valvular heart disease other than significant mitral stenosis and mechanical valves : a meta-analysis", Circulation, 135, pp.714~716 (2017)
98. Kim JY, "Outcomes of direct oral anticoagulants in patients with mitral stenosis", J Am Coll Cardiol, 73, pp.1123~1131 (2019)
99. Lip GYH, "Antithrombotic therapy in atrial fibrillation associated with valvular heart disease : a joint consensus document from the European Heart Rhythm Association(EHRA)and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa(CASSA), Heart Rhythm Society(HRS), Asia Pacific Heart Rhythm Society(APHRS), South African Heart(SA Heart)Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia(SOLEACE)", Europace, 19, pp.1757~1758 (2017)
100. Bisson A, "Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification", Int J Cardiol, 260, pp.93~98 (2018)
101. Seeger J, "Apixaban in patients with atrial fibrillation after transfemoral aortic valve replacement", JACC Cardiovasc Interv, 10, pp.66~74 (2017)
102. Dangas GD, "A controlled trial of rivaroxaban after transcatheter aortic-valve replacement", N Engl J Med, 382, pp.120~129 (2020)
103. Eikelboom JW, "Dabigatran versus warfarin in patients with mechanical heart valves", N Engl J Med, 369, pp.1206~1214 (2013)
104. Potpara TS, "Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction", Nat Rev Nephrol, 14, pp.337~351 (2018)
105. Olesen JB, "Stroke and bleeding in atrial fibrillation with chronic kidney disease", N Engl J Med, 367, pp.625~635 (2012)
106. Zimmerman D, "Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis", Nephrol Dial Transplant, 27, pp.3816~3822 (2012)
107. Banerjee A, "A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation : the Loire Valley Atrial Fibrillation Project", Chest, 145, pp.1370~1382 (2014)
108. Fauchier L, "Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation", Am Heart J, 198, pp.39~45 (2018)
109. Bohula EA, "Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial", Circulation, 134, pp.24~36 (2016)
110. Hijazi Z, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation : a RE-LY(randomized evaluation of long-term anticoagulation therapy)trial analysis", Circulation, 129, pp.961~970 (2014)
111. Fox KA, "Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment", Eur Heart J, 32, pp.2387~2394 (2011)
112. Hohnloser SH, "Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation : insights from the ARISTOTLE trial", Eur Heart J, 33, pp.2821~2830 (2012)
113. Siontis KC, "Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States", Circulation, 138, pp.1519~1529 (2018)
114. Coleman CI, "Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis", Am J Med, 132, pp.1078~1083 (2019)
115. Ha JT, "Benefits and harms of oral anticoagulant therapy in chronic kidney disease : a systematic review and meta-analysis", Ann Intern Med, 171, pp.181~189 (2019)
116. Violi F, "Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation : implications for risk and therapy", J Am Coll Cardiol, 62, pp.2255~2256 (2013)
117. Anandasundaram B, "The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients : a systematic review", J Thromb Haemost, 11, pp.975~987 (2013)
118. Pastori D, "Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants", Int J Cardiol, 264, pp.58~63 (2018)
119. Gorenek B, "European Heart Rhythm Association(EHRA)position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society(APHRS)and Latin American Heart Rhythm Society(LAHRS)", Europace, 20, pp.895~896 (2018)
120. Bruere H, "History of thyroid disorders in relation to clinical outcomes in atrial fibrillation", Am J Med, 128, pp.30~37 (2015)
121. Nakazawa HK, "Management of atrial fibrillation in the post-thyrotoxic state", Am J Med, 72, pp.903~906 (1982)
122. Kristensen SL, "Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease : a nationwide study", Europace, 16, pp.477~484 (2014)
123. Holster IL, "New oral anticoagulants increase risk for gastrointestinal bleeding : a systematic review and meta-analysis", Gastroenterology, 145, pp.105~112 (2013)
124. Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
125. Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
126. Kolb JM, "Locations and mucosal lesions responsible for major gastrointestinal bleeding in patients on warfarin or dabigatran", Dig Dis Sci, 63, pp.1878~1889 (2018)
127. Chai-Adisaksopha C, "Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis", Thromb Haemost, 114, pp.819~825 (2015)
128. O'Dea D, "A prospective, randomized, open-label study to evaluate two management strategies for gastrointestinal symptoms in patients newly on treatment with dabigatran", Cardiol Ther, 5, pp.187~201 (2016)
129. Lai HC, "Atrial fibrillation, liver disease, antithrombotics and risk of cerebrovascular events : a population-based cohort study", Int J Cardiol, 223, pp.829~837 (2016)
130. Lip GY, "Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation : the HAS-BLED(hypertension, abnormal renal", liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs, J Am Coll Cardiol, pp.2011, 57[DOI]
131. Hoolwerf EW, "Direct oral anticoagulants in patients with liver cirrhosis : a systematic review", Thromb Res, 170, pp.102~108 (2018)
132. Lee SR, "Direct oral anticoagulants in patients with atrial fibrillation and liver disease", J Am Coll Cardiol, 73, pp.3295~3308 (2019)
133. Kuo L, "Liver cirrhosis in patients with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention?", J Am Heart Assoc, 6, pp.e005307~ (2017)
134. Kubitza D, "Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor", Br J Clin Pharmacol, 76, pp.89~98 (2013)
135. O'Brien EC, "The ORBIT bleeding score : a simple bedside score to assess bleeding risk in atrial fibrillation", Eur Heart J, 36, pp.3258~3264 (2015)
136. Hijazi Z, "The novel biomarker-based ABC(age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation : a derivation and validation study", Lancet, 387, pp.2302~2311 (2016)
137. Bonde AN, "Oral anticoagulation among atrial fibrillation patients with anaemia : an observational cohort study", Eur Heart J, 40, pp.3782~3790 (2019)
138. Arun M, "The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation : experience at a single institution", Bone Marrow Transplant, 52, pp.1349~1351 (2017)
139. Yuan M, "The incidence of atrial fibrillation with trastuzumab treatment: a systematic review and meta-analysis", Cardiovasc Ther., 36, pp.e12475~ (2018)
140. Ganatra S, "Ibrutinib-associated atrial fibrillation", JACC Clin Electrophysiol, 4, pp.1491~1500 (2018)
141. Boriani G, "Practical management of ibrutinib in the real life : Focus on atrial fibrillation and bleeding", Hematol Oncol, 36, pp.624~632 (2018)
142. Yun S, "Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment : a systematic review and pooled analysis of four randomized controlled trials", Clin Lymphoma Myeloma Leuk, 17, pp.31~37 (2017)
143. Schnabel RB, "50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study : a cohort study", Lancet, 386, pp.154~162 (2015)
144. Feinberg WM, "Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications", Arch Intern Med, 155, pp.469~473 (1995)
145. Zoni-Berisso M, "Epidemiology of atrial fibrillation : European perspective", Clin Epidemiol, 6, pp.213~220 (2014)
146. Hijazi Z, "The ABC(age, biomarkers, clinical history)stroke risk score : a biomarker-based risk score for predicting stroke in atrial fibrillation", Eur Heart J, 37, pp.1582~1590 (2016)
147. Marinigh R, "Age as a risk factor for stroke in atrial fibrillation patients : implications for thromboprophylaxis", J Am Coll Cardiol, 56, pp.827~837 (2010)
148. Stroke Risk in Atrial Fibrillation Working G, "Independent predictors of stroke in patients with atrial fibrillation : a systematic review", Neurology, 69, pp.546~554 (2007)
149. Graham DJ, "Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation", Circulation, 131, pp.157~164 (2015)
150. Biteker M, "Real-world clinical characteristics and treatment patterns of individuals aged 80and older with nonvalvular atrial fibrillation : results from the ReAl-life multicenter survey evaluating stroke study", J Am Geriatr Soc, 65, pp.1684~1690 (2017)
151. Gage BF, "Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation", Stroke, 31, pp.822~827 (2000)
152. Ghaswalla PK, "Warfarin use in nursing home residents : results from the 2004 national nursing home survey", Am J Geriatr Pharmacother, 10, pp.25~36 (2012)
153. Kotecha D, "Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction : a systematic review and meta-analysis of death and adverse outcomes", Int J Cardiol, 203, pp.660~666 (2016)
154. Oqab Z, "What is the impact of frailty on prescription of anticoagulation in elderly patients with atrial fibrillation? A systematic review and meta-analysis", J Atr Fibrillation, 10, pp.1870~ (2018)
155. Proietti M, "'Real-world' atrial fibrillation management in Europe : observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase", Europace, 19, pp.722~733 (2017)
156. Singh P, "Evaluation of antithrombotic usage for atrial fibrillation in aged care facilities", J Clin Pharm Ther, 36, pp.166~171 (2011)
157. Annoni G, "Real-world characteristics of hospitalized frail elderly patients with atrial fibrillation : can we improve the current prescription of anticoagulants?", J Geriatr Cardiol, 13, pp.226~232 (2016)
158. Deandrea S, "Risk factors for falls in older people in nursing homes and hospitals. A systematic review and meta-analysis", Arch Gerontol Geriatr, 56, pp.407~415 (2013)
159. Phelan EA, "Assessment and management of fall risk in primary care settings", Med Clin North Am, 99, pp.281~293 (2015)
160. Lip GY, "Stroke and major bleeding risk in elderly patients aged >", =75 years with atrial fibrillation : the Loire Valley atrial fibrillation project, 2015, pp.46, 143~150
161. Man-Son-Hing M, "Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls", Arch Intern Med, 159, pp.677~685 (1999)
162. Gage BF, "Clinical classification schemes for predicting hemorrhage : results from the National Registry of Atrial Fibrillation(NRAF)", Am Heart J, 151, pp.713~719 (2006)
163. Donze J, "Risk of falls and major bleeds in patients on oral anticoagulation therapy", Am J Med, 125, pp.773~778 (2012)
164. Garwood CL, "Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls", Ann Pharmacother, 42, pp.523~532 (2008)
165. Hart RG, "Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation", Ann Intern Med, 147, pp.590~592 (2007)
166. Rash A, "A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation(WASPO)", Age Ageing, 36, pp.151~156 (2007)
167. Mant J, "Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation(the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA) : a randomised controlled trial", Lancet, 370, pp.493~503 (2007)
168. Sardar P, "New oral anticoagulants in elderly adults : evidence from a meta-analysis of randomized trials", J Am Geriatr Soc, 62, pp.857~864 (2014)
169. Chao TF, "Oral anticoagulation in very elderly patients with atrial fibrillation : a nationwide cohort study", Circulation, 138, pp.37~47 (2018)
170. Siu CW, "Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation", Circ Arrhythm Electrophysiol, 7, pp.300~306 (2014)
171. Mozaffarian D, "Heart disease and stroke statistics--2015 update: a report from the American Heart Association", Circulation, 131, pp.e29~e322 (2015)
172. Alnsasra H, "Net clinical benefit of anticoagulant treatments in elderly patients with nonvalvular atrial fibrillation : experience from the real world", Heart Rhythm, 16, pp.31~37 (2019)
173. Deitelzweig S, "Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation patients", J Am Geriatr Soc, 67, pp.1662~1671 (2019)
174. Dillinger JG, "Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation : why we should not underdose our patients", Arch Cardiovasc Dis, 111, pp.85~94 (2018)
175. Nieuwlaat R, "Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation", Am Heart J, 153, pp.1006~1012 (2007)
176. Fumagalli S, "Age-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in europe : the EORP-AF general pilot registry(EURObservational Research Programme-Atrial Fibrillation)", JACC Clin Electrophysiol, 1, pp.326~334 (2015)
177. Paciullo F, "Choice and outcomes of rate control versus rhythm control in elderly patients with atrial fibrillation : a report from the REPOSI study", Drugs Aging, 35, pp.365~373 (2018)
178. Shariff N, "Rate-control versus rhythm-control strategies and outcomes in septuagenarians with atrial fibrillation", Am J Med, 126, pp.887~893 (2013)
179. Purmah Y, "Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation", Europace, 20, pp.243~252 (2018)
180. Abdin A, "Safety and efficacy of cryoballoon ablation for the treatment of atrial fibrillation in elderly patients", Clin Res Cardiol, 108, pp.167~174 (2019)
181. Bhargava M, "Impact of age on the outcome of pulmonary vein isolation for atrial fibrillation using circular mapping technique and cooled-tip ablation catheter", J Cardiovasc Electrophysiol, 15, pp.8~13 (2004)
182. Bulava A, "Clinical outcomes of radiofrequency catheter ablation of atrial fibrillation in octogenarians-10-year experience of a one high-volume center", J Geriatr Cardiol, 14, pp.575~581 (2017)
183. Bunch TJ, "Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in octogenarians", Pacing Clin Electrophysiol, 33, pp.146~152 (2010)
184. Heeger CH, "Efficacy and safety of cryoballoon ablation in patients with heart failure and reduced left ventricular ejection fraction-a multicenter study", Circ J, 83, pp.1653~1659 (2019)
185. Kis Z, "Comparison of long-term outcome between patients aged < 65 years vs. >", = 65 years after atrial fibrillation ablation, 2017, pp.14, 569~574
186. Lin T, "Long-term results of single-procedure catheter ablation for atrial fibrillationin preand post-menopausal women", J Geriatr Cardiol, 11, pp.120~125 (2014)
187. Lioni L, "Catheter ablation of atrial fibrillation in the elderly", J Geriatr Cardiol, 11, pp.291~295 (2014)
188. Metzner I, "Ablation of atrial fibrillation in patients >", =75 years : long-term clinical outcome and safety, 2016, pp.18, 543~549
189. Santangeli P, "Catheter ablation of atrial fibrillation in octogenarians : safety and outcomes", J Cardiovasc Electrophysiol, 23, pp.687~693 (2012)
190. Tan HW, "Efficacy, safety and outcome of catheter ablation for atrial fibrillation in octogenarians", Int J Cardiol, 145, pp.147~148 (2010)
191. Zado E, "Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in the elderly", J Cardiovasc Electrophysiol, 19, pp.621~626 (2008)
192. Abugattas JP, "Efficacy and safety of the second generation cryoballoon ablation for the treatment of paroxysmal atrial fibrillation in patients over 75 years : a comparison with a younger cohort", Europace, 19, pp.1798~1803 (2017)
193. Bunch TJ, "The impact of age on 5-year outcomes after atrial fibrillation catheter ablation", J Cardiovasc Electrophysiol, 27, pp.141~146 (2016)
194. Guiot A, "Anticoagulant therapy and risk of cerebrovascular events after catheter ablation of atrial fibrillation in the elderly", J Cardiovasc Electrophysiol, 23, pp.36~43 (2012)
195. Kusumoto F, "Radiofrequency catheter ablation of atrial fibrillation in older patients : outcomes and complications", J Interv Card Electrophysiol, 25, pp.31~35 (2009)
196. Liu Y, "Catheter ablation of atrial fibrillation in Chinese elderly patients", Int J Cardiol, 152, pp.266~267 (2011)
197. Shah RU, "Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation", J Am Coll Cardiol, 59, pp.143~149 (2012)
198. Spragg DD, "Complications of catheter ablation for atrial fibrillation : incidence and predictors", J Cardiovasc Electrophysiol, 19, pp.627~631 (2008)
199. Srivatsa UN, "Risk predictors of stroke and mortality after ablation for atrial fibrillation : the California experience 2005-2009", Heart Rhythm, 11, pp.1898~1903 (2014)
200. Friberg L, "Less dementia with oral anticoagulation in atrial fibrillation", Eur Heart J, 39, pp.453~460 (2018)
201. Jacobs V, "Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia", Heart Rhythm, 11, pp.2206~2213 (2014)
202. Jacobs V, "Percent time with a supratherapeutic INR in atrial fibrillation patients also using an antiplatelet agent is associated with long-term risk of dementia", J Cardiovasc Electrophysiol, 26, pp.1180~1186 (2015)
203. Jacobs V, "Long-term population-based cerebral ischemic event and cognitive outcomes of direct oral anticoagulants compared with warfarin among long-term anticoagulated patients for atrial fibrillation", Am J Cardiol, 118, pp.210~214 (2016)
204. Zhang C, "Non-vitamin K antagonist oral anticoagulants and cognitive impairment in atrial fibrillation : insights from the meta-analysis of over 90, 000patients of randomized controlled trials and real-world studies", Front Aging Neurosci, 10, pp.258~ (2018)
205. Sogaard M, "Nonvitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients and risk of dementia: a nationwide propensity-weighted cohort study", J Am Heart Assoc, 8, pp.e011358~ (2019)
206. Friberg L, "Less dementia and stroke in low-risk patients with atrial fibrillation taking oral anticoagulation", Eur Heart J, 40, pp.2327~2335 (2019)
207. Dagres N, "European Heart Rhythm Association (EHRA)", Heart Rhythm Society (HRS), Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?, pp.Heart Rhythm, 2018[DOI]
208. Okuno J, "Is cognitive impairment a risk factor for poor compliance among Japanese elderly in the community?", Eur J Clin Pharmacol, 57, pp.589~594 (2001)
209. Salas M, "Impaired cognitive function and compliance with antihypertensive drugs in elderly : the Rotterdam Study", Clin Pharmacol Ther, 70, pp.561~566 (2001)
210. Kirchhof P, "Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation", Eur Heart J, 39, pp.2942~2955 (2018)
211. Jensen AS, "Anticoagulation in adults with congenital heart disease : the who, the when and the how?", Heart, 101, pp.424~429 (2015)
212. Renda G, "Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease", J Am Coll Cardiol, 69, pp.1363~1371 (2017)
213. Caldeira D, "Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease : systematic review and meta-analysis", Eur Heart J Cardiovasc Pharmacother, 4, pp.111~118 (2018)
214. Ammash NM, "Outcome of direct current cardioversion for atrial arrhythmias in adults with congenital heart disease", Int J Cardiol, 154, pp.270~274 (2012)
215. Feltes TF, "Transesophageal echocardiographic detection of atrial thrombi in patients with nonfibrillation atrial tachyarrhythmias and congenital heart disease", J Am Coll Cardiol, 24, pp.1365~1370 (1994)
216. Roos-Hesselink JW, "Excellent survival and low incidence of arrhythmias, stroke and heart failure long-term after surgical ASD closure at young age. A prospective follow-up study of 21-33 years", Eur Heart J, 24, pp.190~197 (2003)
217. Mas JL, "Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke", N Engl J Med, 377, pp.1011~1021 (2017)
218. Gutierrez SD, "Atrial tachyarrhythmias and the Cox-maze procedure in congenital heart disease", Congenit Heart Dis, 8, pp.434~439 (2013)
219. Kobayashi J, "Maze procedure for atrial fibrillation associated with atrial septal defect", Circulation, 98, pp.ll399~ll402 (1998)
220. 심훈보, "Efficacy of the Maze Procedure for Atrial Fibrillation Associated with Atrial Septal Defect", Journal of Chest Surgery, 46(2), pp.98~103 (2013), 대한심장혈관흉부외과학회
221. Sherwin ED, "Update on interventional electrophysiology in congenital heart disease : evolving solutions for complex hearts", Circ Arrhythm Electrophysiol, 6, pp.1032~1040 (2013)
222. Kusano KF, "Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds", J Am Coll Cardiol, 51, pp.1169~1175 (2008)
223. Francis J, "Atrial fibrillation and Brugada syndrome", J Am Coll Cardiol, 51, pp.1149~1153 (2008)
224. Sy RW, "Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia", Heart Rhythm, 8, pp.864~871 (2011)
225. Sumitomo N, "Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia", Circ J, 71, pp.1606~1609 (2007)
226. Zellerhoff S, "Atrial arrhythmias in long-QT syndrome under daily life conditions : a nested case control study", J Cardiovasc Electrophysiol, 20, pp.401~407 (2009)
227. Chu AF, "Atrial arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy", dysplasia and ventricular tachycardia, 2010, pp.106, 720~722
228. Siontis KC, "Atrial fibrillation in hypertrophic cardiomyopathy:prevalence, clinical correlations, and mortality in a large high-risk population", J Am Heart Assoc., 3, pp.e001002~ (2014)
229. Stollberger C, "Atrial fibrillation in left ventricular noncompaction with and without neuromuscular disorders is associated with a poor prognosis", Int J Cardiol, 133, pp.41~45 (2009)
230. Klopotowski M, "Clinical and echocardiographic parameters as risk factors for atrial fibrillation in patients with hypertrophic cardiomyopathy", Clin Cardiol, 41, pp.1336~1340 (2018)
231. Aras D, "Clinical features of isolated ventricular noncompaction in adults long-term clinical course, echocardiographic properties, and predictors of left ventricular failure", J Card Fail, 12, pp.726~733 (2006)
232. Saguner AM, "Clinical role of atrial arrhythmias in patients with arrhythmogenic right ventricular dysplasia", Circ J, 78, pp.2854~2861 (2014)
233. Tonet JL, "Frequency of supraventricular tachyarrhythmias in arrhythmogenic right ventricular dysplasia", Am J Cardiol, 67, pp.1153~ (1991)
234. van Rijsingen IA, "Gender-specific differences in major cardiac events and mortality in lamin A", C mutation carriers, 2013, pp.15, 376~384
235. Li S, "Genotype-positive status is associated with poor prognoses in patients with left ventricular noncompaction cardiomyopathy", J Am Heart Assoc., 7, pp.e009910~ (2018)
236. van Velzen HG, "Incidence of device-detected atrial fibrillation and long-term outcomes in patients with hypertrophic cardiomyopathy", Am J Cardiol, 119, pp.100~105 (2017)
237. Bordachar P, "Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada syndrome", Eur Heart J, 25, pp.879~884 (2004)
238. Bourfiss M, "Influence of genotype on structural atrial abnormalities and atrial fibrillation or flutter in arrhythmogenic right ventricular dysplasia", cardiomyopathy, 2016, pp.27, 1420~1428
239. Hasselberg NE, "Lamin A", C cardiomyopathy : young onset, high penetrance, and frequent need for heart transplantation, 2018, pp.39, 853~860
240. Kumar S, "Long-term arrhythmic and nonarrhythmic outcomes of lamin A", C mutation carriers, 2016, pp.68, 2299~2307
241. Pasotti M, "Long-term outcome and risk stratification in dilated cardiolaminopathies", J Am Coll Cardiol, 52, pp.1250~1260 (2008)
242. Sacher F, "Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome : a multicenter study-part 2", Circulation, 128, pp.1739~1747 (2013)
243. Hernandez-Ojeda J, "Patients with Brugada syndrome and implanted cardioverter-defibrillators : long-term follow-up", J Am Coll Cardiol, 70, pp.1991~2002 (2017)
244. Camm CF, "Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia", cardiomyopathy, 2013, pp.10, 1661~1668
245. Johnson JN, "Prevalence of early-onset atrial fibrillation in congenital long QT syndrome", Heart Rhythm, 5, pp.704~709 (2008)
246. Rodriguez-Manero M, "Prevalence, clinical characteristics and management of atrial fibrillation in patients with Brugada syndrome", Am J Cardiol, 111, pp.362~367 (2013)
247. Borggrefe M, "Short QT syndrome. Genotype-phenotype correlations", J Electrocardiol, 38, pp.75~80 (2005)
248. Gaita F, "Short QT syndrome : a familial cause of sudden death", Circulation, 108, pp.965~970 (2003)
249. Giustetto C, "Short QT syndrome : clinical findings and diagnostic-therapeutic implications", Eur Heart J, 27, pp.2440~2447 (2006)
250. Gollob MH, "The short QT syndrome : proposed diagnostic criteria", J Am Coll Cardiol, 57, pp.802~812 (2011)
251. Mussigbrodt A, "Supraventricular arrhythmias in patients with arrhythmogenic right ventricular dysplasia", cardiomyopathy associate with long-term outcome after catheter ablation of ventricular tachycardias, 2018, pp.20, 1182~1187
252. Choi YJ, "Temporal trends of the prevalence and incidence of atrial fibrillation and stroke among Asian patients with hypertrophic cardiomyopathy : a nationwide population-based study", Int J Cardiol, 273, pp.130~135 (2018)
253. Peters S, "Atrial arrhythmias in arrhythmogenic cardiomyopathy : at the beginning or at the end of the disease story?", Circ J, 79, pp.446~ (2015)
254. Olesen MS, "High prevalence of long QT syndrome-associated SCN5A variants in patients with early-onset lone atrial fibrillation", Circ Cardiovasc Genet, 5, pp.450~459 (2012)
255. Fatkin D, "Missense mutations in the rod domain of the lamin A", C gene as causes of dilated cardiomyopathy and conduction-system disease, 1999, pp.341, 1715~1724
256. Pappone C, "New-onset atrial fibrillation as first clinical manifestation of latent Brugada syndrome : prevalence and clinical significance", Eur Heart J, 30, pp.2985~2992 (2009)
257. Hong K, "Short QT syndrome and atrial fibrillation caused by mutation in KCNH2", J Cardiovasc Electrophysiol, 16, pp.394~396 (2005)
258. Mazzanti A, "Arrhythmogenic right ventricular cardiomyopathy : clinical course and predictors of arrhythmic risk", J Am Coll Cardiol, 68, pp.2540~2550 (2016)
259. Giustetto C, "Atrial fibrillation in a large population with Brugada electrocardiographic pattern : prevalence, management, and correlation with prognosis", Heart Rhythm, 11, pp.259~265 (2014)
260. Rowin EJ, "Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy", Circulation, 136, pp.2420~2436 (2017)
261. Conte G, "Drug-induced Brugada syndrome in children : clinical features, device-based management, and long-term follow-up", J Am Coll Cardiol, 63, pp.2272~2279 (2014)
262. Maron BJ, "Epidemiology of hypertrophic cardiomyopathy-related death : revisited in a large non-referral-based patient population", Circulation, 102, pp.858~864 (2000)
263. Lee SE, "Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy", Heart, 103, pp.1496~1501 (2017)
264. Olivotto I, "Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy", Circulation, 104, pp.2517~2524 (2001)
265. Pizzale S, "Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation", J Cardiovasc Electrophysiol, 19, pp.1319~1321 (2008)
266. Sugiyasu A, "A case with catecholaminergic polymorphic ventricular tachycardia unmasked after successful ablation of atrial tachycardias from pulmonary veins", Pacing Clin Electrophysiol., 32, pp.e21~e24 (2009)
267. Veltmann C, "Prevention of inappropriate ICD shocks in patients with Brugada syndrome", Clin Res Cardiol, 99, pp.37~44 (2010)
268. Klein GJ, "Ventricular fibrillation in the Wolff-Parkinson-White syndrome", N Engl J Med, 301, pp.1080~1085 (1979)
269. Brugada J, "2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology(ESC)", Eur Heart J, 41, pp.655~720 (2020)
270. Sellers TD Jr, "Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation", Circulation, 56, pp.260~267 (1977)
271. Morady F, "Effect of propranolol on ventricular rate during atrial fibrillation in the Wolff-Parkinson-White syndrome", Pacing Clin Electrophysiol, 10, pp.492~496 (1987)
272. Glatter KA, "Electrophysiological effects of ibutilide in patients with accessory pathways", Circulation, 104, pp.1933~1939 (2001)
273. Ludmer PL, "Efficacy of propafenone in Wolff-Parkinson-White syndrome : electrophysiologic findings and long-term follow-up", J Am Coll Cardiol, 9, pp.1357~1363 (1987)
274. Crijns HJ, "Successful use of flecainide in atrial fibrillation with rapid ventricular rate in the Wolff-Parkinson-White syndrome", Am Heart J, 115, pp.1317~1321 (1988)
275. Boahene KA, "Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone : importance of atrial fibrillatory cycle length", J Am Coll Cardiol, 16, pp.1408~1414 (1990)
276. Simonian SM, "Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation", Intern Emerg Med, 5, pp.421~426 (2010)
277. Drenthen W, "Outcome of pregnancy in women with congenital heart disease : a literature review", J Am Coll Cardiol, 49, pp.2303~2311 (2007)
278. Opotowsky AR, "Maternal cardiovascular events during childbirth among women with congenital heart disease", Heart, 98, pp.145~151 (2012)
279. Lee MS, "Atrial fibrillation and atrial flutter in pregnant women-a population-based study", J Am Heart Assoc, 5, pp.e003182~ (2016)
280. Li JM, "Frequency and outcome of arrhythmias complicating admission during pregnancy : experience from a high-volume and ethnically-diverse obstetric service", Clin Cardiol, 31, pp.538~541 (2008)
281. Vaidya VR, "Burden of Arrhythmia in Pregnancy", Circulation, 135, pp.619~621 (2017)
282. Regitz-Zagrosek V, "2018 ESC guidelines for the management of cardiovascular diseases during pregnancy", Eur Heart J, 39, pp.3165~3241 (2018)
283. Wang YC, "The impact of maternal cardioversion on fetal haemodynamics", Eur J Obstet Gynecol Reprod Biol, 126, pp.268~269 (2006)
284. Moore JS, "Maternal arrhythmia : a case report and review of the literature", Obstet Gynecol Surv, 67, pp.298~312 (2012)
285. Page RL, "Treatment of arrhythmias during pregnancy", Am Heart J, 130, pp.871~876 (1995)
286. Barnes EJ, "Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section", BJOG, 109, pp.1406~1407 (2002)
287. Heidbuchel H, "Endurance sports is a risk factor for atrial fibrillation after ablation for atrial flutter", Int J Cardiol, 107, pp.67~72 (2006)
288. Abdulla J, "Is the risk of atrial fibrillation higher in athletes than in the general population? A systematic review and meta-analysis", Europace, 11, pp.1156~1159 (2009)
289. Karjalainen J, "Lone atrial fibrillation in vigorously exercising middle aged men : case-control study", BMJ, 316, pp.1784~1785 (1998)
290. Calvo N, "Emerging risk factors and the dose-response relationship between physical activity and lone atrial fibrillation : a prospective case-control study", Europace, 18, pp.57~63 (2016)
291. Crump C, "Height, weight, and aerobic fitness level in relation to the risk of atrial fibrillation", Am J Epidemiol, 187, pp.417~426 (2018)
292. Mont L, "Long-lasting sport practice and lone atrial fibrillation", Eur Heart J, 23, pp.477~482 (2002)
293. Mont L, "Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals", Europace, 10, pp.15~20 (2008)
294. Guasch E, "Diagnosis, pathophysiology, and management of exercise-induced arrhythmias", Nat Rev Cardiol, 14, pp.88~101 (2017)
295. Kirchhof P, "2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS", Eur Heart J, 37, pp.2893~2962 (2016)
296. Baldesberger S, "Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists", Eur Heart J, 29, pp.71~78 (2008)
297. Stein R, "Intrinsic sinus and atrioventricular node electrophysiologic adaptations in endurance athletes", J Am Coll Cardiol, 39, pp.1033~1038 (2002)
298. Alboni P, "Outpatient treatment of recent-onset atrial fibrillation with the"pill-in-the-pocket"approach", N Engl J Med, 351, pp.2384~2391 (2004)
299. Calvo N, "Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes", Europace, 12, pp.30~36 (2010)
300. Koopman P, "Efficacy of radiofrequency catheter ablation in athletes with atrial fibrillation", Europace, 13, pp.1386~1393 (2011)
301. O'Brien B, "Society of Cardiovascular Anesthesiologists", European Association of Cardiothoracic Anaesthetists practice advisory for the management of perioperative atrial fibrillation in patients undergoing cardiac surgery, 2019, pp.33, 12~26
302. Dobrev D, "Postoperative atrial fibrillation : mechanisms, manifestations and management", Nat Rev Cardiol, 16, pp.417~436 (2019)
303. Lubitz SA, "Long-term outcomes of secondary atrial fibrillation in the community : the Framingham Heart Study", Circulation, 131, pp.1648~1655 (2015)
304. Amar D, "Postthoracotomy atrial fibrillation", Curr Opin Anaesthesiol, 20, pp.43~47 (2007)
305. Philip I, "Perioperative challenges of atrial fibrillation", Curr Opin Anaesthesiol, 27, pp.344~352 (2014)
306. Konstantino Y, "Postoperative atrial fibrillation following coronary artery bypass graft surgery predicts long-term atrial fibrillation and stroke", Isr Med Assoc J, 18, pp.744~748 (2016)
307. Lee SH, "New-onset atrial fibrillation predicts long-term newly developed atrial fibrillation after coronary artery bypass graft", Am Heart J, 167, pp.593~600 (2014)
308. Lin MH, "Perioperative", postoperative atrial fibrillation and risk of subsequent stroke and, Stroke, pp.2019, 50[DOI]
309. AlTurki A, "Major adverse cardiovascular events associated with postoperative atrial fibrillation after noncardiac surgery: a systematic review and meta-analysis", Circ Arrhythm Electrophysiol., 13, pp.e007437~ (2020)
310. Mathew JP, "A multicenter risk index for atrial fibrillation after cardiac surgery", JAMA, 291, pp.1720~1729 (2004)
311. Villareal RP, "Postoperative atrial fibrillation and mortality after coronary artery bypass surgery", J Am Coll Cardiol, 43, pp.742~748 (2004)
312. Cardinale D, "Prevention of atrial fibrillation in high-risk patients undergoing lung cancer surgery : the PRESAGE trial", Ann Surg, 264, pp.244~251 (2016)
313. Ojima T, "Randomized clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and postoperative complications after oesophagectomy for cancer", Br J Surg, 104, pp.1003~1009 (2017)
314. Arsenault KA, "Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery", Cochrane Database Syst Rev., 2013, pp.CD003611~ (2013)
315. Ozaydin M, "Metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine on post-operative atrial fibrillation: a randomized, double-blind, placebo-controlled study", Eur Heart J, 34, pp.597~604 (2013)
316. O'Neal JB, "Effect of preoperative beta-blocker use on outcomes following cardiac surgery", Am J Cardiol, 120, pp.1293~1297 (2017)
317. Group PS, "Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery(POISE trial) : a randomised controlled trial", Lancet, 371, pp.1839~1847 (2008)
318. Zhu J, "Meta-analysis of amiodarone versus beta-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery", Intern Med J, 42, pp.1078~1087 (2012)
319. Auer J, "A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery : the pilot study of prevention of postoperative atrial fibrillation(SPPAF), a randomized, placebo-controlled trial", Am Heart J, 147, pp.636~643 (2004)
320. Buckley MS, "Amiodarone prophylaxis for atrial fibrillation after cardiac surgery : meta-analysis of dose response and timing of initiation", Pharmacotherapy, 27, pp.360~368 (2007)
321. Riber LP, "Amiodarone significantly decreases atrial fibrillation in patients undergoing surgery for lung cancer", Ann Thorac Surg, 94, pp.339~346 (2012)
322. Tisdale JE, "A randomized trial evaluating amiodarone for prevention of atrial fibrillation after pulmonary resection", Ann Thorac Surg, 88, pp.886~895 (2009)
323. Yuan X, "Defining the role of perioperative statin treatment in patients after cardiac surgery : a meta-analysis and systematic review of 20 randomized controlled trials", Int J Cardiol, 228, pp.958~966 (2017)
324. Zheng Z, "Perioperative rosuvastatin in cardiac surgery", N Engl J Med, 374, pp.1744~1753 (2016)
325. Fairley JL, "Magnesium status and magnesium therapy in cardiac surgery : a systematic review and meta-analysis focusing on arrhythmia prevention", J Crit Care, 42, pp.69~77 (2017)
326. Tabbalat RA, "Effect of colchicine on the incidence of atrial fibrillation in open heart surgery patients : END-AF trial", Am Heart J, 178, pp.102~107 (2016)
327. Ali-Hasan-Al-Saegh S, "Posterior pericardiotomy in cardiac surgery : systematic review and meta-analysis", Asian Cardiovasc Thorac Ann, 23, pp.354~362 (2015)
328. Hu XL, "Posterior pericardiotomy for the prevention of atrial fibrillation after coronary artery bypass grafting : a meta-analysis of randomized controlled trials", Int J Cardiol, 215, pp.252~256 (2016)
329. Wang W, "Clinical efficacy of epicardial application of drug-releasing hydrogels to prevent postoperative atrial fibrillation", J Thorac Cardiovasc Surg, 151, pp.80~85 (2016)
330. Dieleman JM, "Intraoperative high-dose dexamethasone for cardiac surgery : a randomized controlled trial", JAMA, 308, pp.1761~1767 (2012)
331. Whitlock RP, "Methylprednisolone in patients undergoing cardiopulmonary bypass(SIRS) : a randomised, double-blind, placebo-controlled trial", Lancet, 386, pp.1243~1253 (2015)
332. Saxena A, "Usefulness of postoperative atrial fibrillation as an independent predictor for worse early and late outcomes after isolated coronary artery bypass grafting(multicenter Australian study of 19, 497 patients)", Am J Cardiol, 109, pp.219~225 (2012)
333. Almassi GH, "Atrial fibrillation after cardiac surgery : a major morbid event?", Ann Surg, 226, pp.501~511 (1997)
334. Gialdini G, "Perioperative atrial fibrillation and the long-term risk of ischemic stroke", JAMA, 312, pp.616~622 (2014)
335. Horwich P, "New onset postoperative atrial fibrillation is associated with a long-term risk for stroke and death following cardiac surgery", J Card Surg, 28, pp.8~13 (2013)
336. Ahlsson A, "Postoperative atrial fibrillation in patients undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a doubled cardiovascular mortality", Eur J Cardiothorac Surg, 37, pp.1353~1359 (2010)
337. Rubin DA, "Predictors, prevention, and long-term prognosis of atrial fibrillation after coronary artery bypass graft operations", J Thorac Cardiovasc Surg, 94, pp.331~335 (1987)
338. Butt JH, "Long-term thromboembolic risk in patients with postoperative atrial fibrillation after coronary artery bypass graft surgery and patients with nonvalvular atrial fibrillation", JAMA Cardiol, 3, pp.417~424 (2018)
339. Butt JH, "Risk of thromboembolism associated with atrial fibrillation following noncardiac surgery", J Am Coll Cardiol, 72, pp.2027~2036 (2018)
340. Lip GYH, "Antithrombotic therapy in atrial fibrillation associated with valvular heart disease : executive summary of a joint consensus document from the European Heart Rhythm Association(EHRA)and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa(CASSA), Heart Rhythm Society(HRS), Asia Pacific Heart Rhythm Society(APHRS), South African Heart(SA Heart)Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia(SOLEACE)", Thromb Haemost, 117, pp.2215~2236 (2017)
341. Gillinov AM, "Rate control versus rhythm control for atrial fibrillation after cardiac surgery", N Engl J Med, 374, pp.1911~1921 (2016)
342. Hindricks G, "2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS) : the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC)Developed with the special contribution of the European Heart Rhythm Association(EHRA)of the ESC", Eur Heart J, 42, pp.373~498 (2021)

관련 논문AI추천